Genflow Biosciences Plc GENF

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) will present full results from its canine ageing trial on Friday, as it continues talks with several leading animal health companies. The data will be unveiled at the Animal Longevity Summit in Toronto, and the company is preparing a...

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED.

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO Dr Eric Leire spoke with Proactive's Stephen Gunnion about the company's SLAB trial meeting its primary endpoint, providing what he described as important validation for the company's centenarian SIRT6 therapy platform. The trial involved 24 naturally aged beagles, assessing whether Genflow's therapy could reduce biological age as measured by the Horvath methylation clock. Leire said treated animals showed a clear and consistent improvement signal compared with the saline control. "This is a huge milestone we have been building towar

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) says its SLAB gene therapy trial in ageing dogs has hit its primary endpoint. It's now in talks with major animal health companies about a licensing deal. EnergyPathways PLC (AIM:EPP) has appointed Jacobs as engineering and regulatory partner for its MESH energy storage project in the Irish Sea. It's now pushing towards a key Ofgem funding submission. Itaconix PLC (AIM:ITX, OTCQB:ITXXF, FRA:18G0) is targeting a doubling of revenue to $30 million in the medium term. Half-year revenue already jumped 72% thanks to strong detergent demand. G

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) the London-listed biotechnology company developing gene therapies for age-related diseases, announced on Tuesday that its SLAB clinical trial had met its primary endpoint. The trial, known formally as Sarcopenia and Longevity in Aged...

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED.

LONDON, UK / ACCESS Newswire / September 7, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, today announces the appointment of ON365 Partners Inc. ("ON365") as the Company's investor relations adviser, with immediate effect.

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5), the London-listed longevity research company, said the United States Patent and Trademark Office had granted accelerated examination for the foundational patent application covering its centenarian-derived gene variant. The Track One...

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ...

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) said improvements recorded in its SLAB aged-dog gene therapy trial were maintained three months after dosing, with no adverse events reported, ahead of further study results expected after the trial concludes at the end of...

LONDON, UK / ACCESS Newswire / July 13, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), an emerging leader in the field of longevity research, provides a mid-year operational and corporate summary covering the ...

LONDON, UK / ACCESS Newswire / June 29, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, is pleased to announce that all resolutions proposed at the Annual General ...

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO, Dr Eric Leire, talked with Proactive about the company's upcoming presentation at the Animal Longevity Summit in Toronto, where it will showcase results from its Age Dogs clinical trial evaluating centenarian SIRT6 gene...

LONDON, UK / ACCESS Newswire / June 22, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, today announces Gad Berdugo, Independent Non-Executive Chairman will ...

Notice of Annual General Meeting and Board Changes LONDON, UK / ACCESS Newswire / June 4, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing ...

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ...